Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT (2016 - 2026)

Myriad Genetics has reported EBT over the past 17 years, most recently at -$8.9 million for Q4 2025.

  • Quarterly EBT rose 77.24% to -$8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$395.1 million through Dec 2025, down 220.18% year-over-year, with the annual reading at -$395.1 million for FY2025, 219.92% down from the prior year.
  • EBT was -$8.9 million for Q4 2025 at Myriad Genetics, up from -$26.2 million in the prior quarter.
  • Over five years, EBT peaked at $39.8 million in Q3 2021 and troughed at -$330.6 million in Q2 2025.
  • The 5-year median for EBT is -$34.8 million (2023), against an average of -$48.9 million.
  • Year-over-year, EBT skyrocketed 191.08% in 2021 and then plummeted 788.71% in 2025.
  • A 5-year view of EBT shows it stood at -$43.5 million in 2021, then decreased by 19.77% to -$52.1 million in 2022, then soared by 38.0% to -$32.3 million in 2023, then fell by 21.05% to -$39.1 million in 2024, then soared by 77.24% to -$8.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBT are -$8.9 million (Q4 2025), -$26.2 million (Q3 2025), and -$330.6 million (Q2 2025).